News Quantified

ORMP – oramed pharmaceuticals inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

PhaseV to Present at Upcoming Clinical Trial Events and Scientific Meetings, Highlighting the Value of Machine Learning in Drug Development [Yahoo! Finance]

Scilex Holding repays the remaining balance of convertible debentures [Seeking Alpha]

Oramed Letter to Shareholders [Yahoo! Finance]

Oramed Letter to Shareholders

-1.5%

BEAT

-0.9%

BEAT

1.1%

BEAT

Form 4 ORAMED PHARMACEUTICALS For: Apr 17 Filed by: Reznick Yehuda

Form 3 ORAMED PHARMACEUTICALS For: Apr 01 Filed by: Reznick Yehuda

Form SC 13D ORAMED PHARMACEUTICALS Filed by: KIDRON NADAV

Form 8-K ORAMED PHARMACEUTICALS For: Mar 14

Form 8-K ORAMED PHARMACEUTICALS For: Mar 12

Top News Gainers

11/29 Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 36.2%

11/27 Form 10-K ORAMED PHARMACEUTICALS For: Aug 31 17.9%

1/9 Oramed Pharmaceuticals Issues Letter to Shareholders 14.6%

11/25 Oramed working on first insulin pill for diabetes [Yahoo! Finance News] 12.5%

3/19 Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA 11.9%

11/21 Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology 10.3%

7/15 Form 4 ORAMED PHARMACEUTICALS For: Jul 11 Filed by: Sank Leonard 7.3%

9/20 Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) was given a new $20.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 6.5%

1/28 Oramed Patent in Europe to be Granted for Oral Delivery of Proteins 4.8%

9/16 Form 4 ORAMED PHARMACEUTICALS For: Sep 12 Filed by: RAKIN KEVIN 4.3%

Top News Decliners

11/12 Form 8-K ORAMED PHARMACEUTICALS For: Nov 12 -23.5%

2/26 Oramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock -11.4%

7/2 Oramed Announces Xiaoming Gao Joins Board of Directors -7.8%

11/19 Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event -7.1%

9/11 Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating on the stock. -5.2%

1/23 Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board -4.3%

10/17 Oramed Pharmaceuticals And ORMD-0901 [Seeking Alpha] -4.2%

1/30 Oramed Appoints Dr. Julio Rosenstock to Its Scientific Advisory Board -3.9%

2/26 Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial -3.5%

5/16 Form 8-K ORAMED PHARMACEUTICALS For: May 13 -3.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day